January 19, 2006—Viread (tenofovir),Emtriva (emtricitabine) and Sustiva (efavirenz) taken once a day outperformed thetraditional first-line combo of Sustiva and twice-daily Combivir (AZT plus 3TC) in a study published in the January 19 issue of the New England Journal of Medicine.The study, the first comparing the two treatments, also reported thatthe Viread/Emtriva/Sustiva combo caused fewer side effects than the other cocktail,causing more patients to stick with the treatment.